PHPSX Performance — Pharmaceuticals UltraSector ProFund, Service Class
Data updated: 2026-10-13
PHPSX returned +28.37% year to date and +98.65% over one year to Jul 2026. Annualised returns are +17.96% over 3 years and +8.22% over 5 years. The fund beat its Trading - Leveraged category average: $100 invested three years ago grew to $164, against $136 for the category, and to $199 over one year, against $105. Volatility over the past three years was 31.05% a year. In the 12 months to Jul 2026 the fund took in a net $2.6M, and assets reached $8.58M.
PHPSX Growth of $100
What $100 invested in Pharmaceuticals UltraSector ProFund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Leveraged category average over the same months.
| Period | PHPSX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $199 | $105 |
| 3 years (Aug 2023 – Jul 2026) | $164 | $136 |
| 5 years (Aug 2021 – Jul 2026) | $148 | $130 |
| Since data start (Aug 2019 – Jul 2026) | $215 | $147 |
PHPSX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +28.37% |
| 1 year | +98.65% |
| 3 years (annualised) | +17.96% |
| 5 years (annualised) | +8.22% |
PHPSX Annual Returns
Calendar-year total returns of Pharmaceuticals UltraSector ProFund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +28.37% |
| 2025 | +40.02% |
| 2024 | +0.39% |
| 2023 | −12.10% |
| 2022 | −11.64% |
| 2021 | +15.88% |
| 2020 | +14.38% |
| 2019 (Aug–Dec) | +15.86% |
PHPSX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −2.5% | +5.1% | −9.2% | +9.9% | +1.1% | +21.0% | +2.7% | — | — | — | — | — |
| 2025 | +6.7% | −2.2% | −2.5% | −9.8% | −3.0% | −0.5% | +2.1% | +22.3% | +1.4% | +5.0% | +15.0% | +3.4% |
| 2024 | +0.9% | +8.2% | −4.4% | −11.9% | +1.8% | −2.1% | +12.7% | +4.2% | −1.1% | +4.9% | −0.2% | −10.1% |
| 2023 | −1.0% | −8.1% | −1.8% | +3.2% | −9.6% | +6.0% | +9.5% | −0.6% | −13.4% | −15.0% | +4.2% | +19.3% |
| 2022 | −7.0% | −5.6% | +8.9% | −5.1% | +4.8% | −2.0% | −1.3% | −11.6% | −5.3% | +9.9% | +5.1% | −0.7% |
| 2021 | −0.2% | −1.1% | −0.9% | +1.2% | +4.2% | +1.4% | +4.7% | +0.8% | −7.4% | +3.9% | −1.1% | +10.4% |
| 2020 | −1.1% | −13.9% | −11.3% | +19.4% | +4.6% | −3.4% | +3.6% | +8.9% | −3.3% | −3.7% | +10.6% | +7.9% |
| 2019 | — | — | — | — | — | — | — | −5.5% | +0.7% | +6.2% | +5.1% | +9.2% |
PHPSX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 31.05%
- 3-year Sharpe ratio: 0.43 (vs 4.5% risk-free rate)
- Best month: +22.28% (Aug 2025)
- Worst month: −15.01% (Oct 2023)
PHPSX Fund Flows
Monthly money in and out of Pharmaceuticals UltraSector ProFund, from SEC Form N-PORT.
- 12-month net flow: $2.6M
- 12-month gross sales (incl. reinvestments): $54.3M
- Sales ÷ redemptions: 1.05×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $8.8M | $11.8M | −$3.0M |
| Jun 2026 | $8.9M | $2.9M | $6.0M |
| May 2026 | $2.4M | $2.2M | $192K |
| Apr 2026 | $1.9M | $1.8M | $83K |
| Mar 2026 | $4.1M | $4.5M | −$395K |
| Feb 2026 | $3.0M | $3.3M | −$300K |
| Jan 2026 | $4.7M | $4.9M | −$176K |
| Dec 2025 | $5.9M | $6.2M | −$299K |
| Nov 2025 | $4.5M | $3.6M | $869K |
| Oct 2025 | $2.7M | $3.2M | −$429K |
| Sep 2025 | $3.6M | $3.9M | −$328K |
| Aug 2025 | $3.9M | $3.4M | $438K |
PHPSX Assets Under Management
Net assets of Pharmaceuticals UltraSector ProFund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $8.58M |
| 2026-04-30 | $3.37M |
| 2026-01-31 | $3.78M |
| 2025-10-31 | $2.95M |
| 2025-07-31 | $2.46M |
| 2025-04-30 | $3.05M |
| 2025-01-31 | $2.83M |
| 2024-10-31 | $2.90M |
| 2024-07-31 | $3.10M |
| 2024-04-30 | $2.78M |
| 2024-01-31 | $3.36M |
| 2023-10-31 | $2.48M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.